FDA has sent its first notice of noncompliance to Acceleron Pharma (NSDQ:XLRN), accusing the company of failing to submit summary results information to ClinicalTrials.gov for a Phase 2 trial. The agency sent the company a letter warning of potential noncompliance in July 2020. The National Library of Medicine, a part of the National Institutes of Health, operates the…